Provided herein are enzymatic compositions for protein O-glycosylation and sialylation, methods and systems associated therewith. In particular, the composition for in vivo sialylation of therapeutic proteins. The composition comprises a polypeptide N-acetylgalactosaminyltransferase; a β-1,3-galactosyltransferase; an UDP-Glc/GlcNAc 4-epimerase; a disulfide bond isomerase; and an α-2,3-sialyltransferase or an α-2,6-sialyltransferase. Furthermore, provided herein are compositions for efficient and complete O-glycosylation and di-sialylation of therapeutic proteins.

An automated bender and its method of operation according to some embodiments of the disclosure is provided. The automated bender includes a carousel which has all of the necessary components for bending a variety of conduit sizes provided thereon. The carousel can be rotated to a desired bending position to bend a particular type of conduit. A straight workpiece is fed into the automated bender and a bent workpiece, which may have multiple bends therein, is output from the automated bender. This bending process is performed without manual intervention. Software for achieving same is provided.

Disclosed herein are genetically modified microorganisms and related methods for the enhanced production and export of oligosaccharides. The microorganisms described herein express major facility superfamily proteins such as CDT-1, which allows for the export of oligosaccharides. Variants of CDT-1 exhibit higher activity regarding oligosaccharide export. The microorganisms described herein express formation enzymes for the production of oligosaccharides. Means to export oligosaccharides into the growth medium are provided herein.

The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.

The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.

The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

α2-6-Sialyltransferase (2,6ST) variants having improved α2-6-specific sialidase activity as compared to the native 2,6ST enzymes are described. The variants include GT80 sialyltransferases such as P. damselae Pd2,6ST. Methods for making de-sialylated products and screening sialidase activity are also described.

A bender includes a rotatable bending shoe having at least one channel therein configured to receive a workpiece, a seat proximate to the bending shoe which is configured to receive the workpiece thereon, and a sensor provided on the seat which is configured to sense the presence of the workpiece. In some embodiments, the sensor is configured to sense an end of the workpiece.

Provided herein are genetically modified yeast cells capable of producing one or more human milk oligosaccharides (HMOs) and methods of making such cells. The yeast cells are engineered to comprise a heterologous nucleic acid encoding a transporter protein and one or more heterologous nucleic acids that encode enzymes of a HMO biosynthetic pathway. Also provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.

The invention relates to a method of increasing the number of α2,3,-α2,6-disialylgalactose N-glycans on a glycoprotein by incubating an α2,3-sialylated glycoprotein with an α2,6-sialyltransferase and a sialic acid source. Also provided is a recombinant glycoprotein comprising at least one α2,3,-α2,6-disialylgalactose N-glycan. In a particular embodiment, the recombinant glycoprotein is alpha-1 antitrypsin (AAT).